12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC

Fieldview Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,658 shares of the biopharmaceutical company’s stock, valued at approximately $5,772,000. Alnylam Pharmaceuticals accounts for about 0.9% of Fieldview Capital Management LLC’s portfolio, making the stock its 7th largest position.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALNY. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000. Geneos Wealth Management Inc. increased its position in Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 175 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 50.8% in the second quarter. First Horizon Advisors Inc. now owns 187 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 63 shares during the period. Atlantic Union Bankshares Corp bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $30,000. Finally, Vestmark Advisory Solutions Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $567,000. 92.97% of the stock is owned by institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease — deal includes about $10M upfront plus up to $1.13B in milestones, expanding Alnylam’s RNAi opportunity set beyond liver/rare diseases. Tenaya deal
• Positive Sentiment: Alnylam struck a multi‑year precision‑medicine agreement with Helix to accelerate target discovery and patient stratification — a collaboration that could improve R&D efficiency and help de‑risk development programs. Helix agreement
• Positive Sentiment: Coverage notes a Canada reimbursement decision for AMVUTTRA and ongoing trial progress for pipeline assets — these commercial developments improve near‑term revenue visibility for marketed RNAi drugs. AMVUTTRA reimbursement
• Neutral Sentiment: The market reaction to Tenaya’s stock after the deal (TNYA pulled back after a strong rally) shows partner‑stock volatility but does not directly change Alnylam’s deal economics. TNYA market reaction
• Neutral Sentiment: Short‑interest reports showing “0 shares” / 0.0 days to cover are likely a reporting glitch and are not a real driver of positioning today.
• Negative Sentiment: Multiple insiders, including CEO Yvonne Greenstreet and several EVPs, disclosed share sales (early March filings). Clustered insider selling can create near‑term negative sentiment and add selling pressure despite insiders still holding large stakes. CEO SEC filing InsiderTrades summary
• Negative Sentiment: Recent quarterly results (reported Feb. 12) missed EPS and revenue estimates, which keeps valuation under scrutiny and may limit upside until clearer revenue traction is sustained.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the transaction, the executive vice president owned 36,606 shares of the company’s stock, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 1,775 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the sale, the executive vice president owned 23,406 shares in the company, valued at $7,483,834.44. This trade represents a 7.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 53,923 shares of company stock worth $18,072,087. Company insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ALNY. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Finally, Raymond James Financial restated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Stock Up 0.0%

ALNY stock opened at $320.66 on Monday. The stock has a 50-day simple moving average of $352.25 and a two-hundred day simple moving average of $414.18. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a market capitalization of $42.53 billion, a PE ratio of 187.52 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the company posted ($0.65) earnings per share. The company’s quarterly revenue was up 84.9% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.